BRPI0516476A - vlp antigen conjugates and their use as vaccines - Google Patents

vlp antigen conjugates and their use as vaccines

Info

Publication number
BRPI0516476A
BRPI0516476A BRPI0516476-1A BRPI0516476A BRPI0516476A BR PI0516476 A BRPI0516476 A BR PI0516476A BR PI0516476 A BRPI0516476 A BR PI0516476A BR PI0516476 A BRPI0516476 A BR PI0516476A
Authority
BR
Brazil
Prior art keywords
vlp
antigen
vaccines
compositions
secondary structure
Prior art date
Application number
BRPI0516476-1A
Other languages
Portuguese (pt)
Inventor
Martin F Bachmann
Karl G Proba
Patrik Maurer
Edwin Meijerink
Katrin Schwarz
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Priority claimed from PCT/EP2005/055009 external-priority patent/WO2006037787A2/en
Publication of BRPI0516476A publication Critical patent/BRPI0516476A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

CONJUGADOS DE ANTìGENO DE VLP E SEU USO COMO VACINAS. A presente invenção é relacionada com os campos de biologia, virologia, imunologia e medicina molecular. A invenção fornece uma composição que compreende uma partícula semelhante a vírus (VLP) de um RNA-bacteriáfago e pelo menos um antígeno, em que a VLP é recombinantemente produzida em um hospedeiro, e em que a quantidade de RNA hospedeiro com estrutura secundária compreendida pela VLP é no máximo 20 % da quantidade de RNA hospedeiro com estrutura secundária originalmente compreendida pela VLP; e em que a VLP e o pelo menos um antígeno são ligados um com o outro. A invenção também fornece métodos para a produção das composições da invenção. As composições da invenção são úteis na produção de vacinas para o tratamento de doenças, distúrbios e condições. Além disso, as composições da invenção são particularmente úteis para eficientemente induzir respostas de anticorpo fortes contra o antígeno dentro do contexto indicado enquanto diminui ou elimina as respostas da célula T indesejáveis.VLP ANTIGEN ASSEMBLIES AND THEIR USE AS VACCINES. The present invention relates to the fields of biology, virology, immunology and molecular medicine. The invention provides a composition comprising a virus-like particle (VLP) of a bacteriophage RNA and at least one antigen, wherein the VLP is recombinantly produced in a host, and wherein the amount of secondary structure host RNA comprised by VLP is at most 20% of the amount of secondary structure host RNA originally comprised by VLP; and wherein the VLP and at least one antigen are linked with each other. The invention also provides methods for producing the compositions of the invention. The compositions of the invention are useful in producing vaccines for the treatment of diseases, disorders and conditions. In addition, the compositions of the invention are particularly useful for efficiently inducing strong antigen antibody responses within the indicated context while decreasing or eliminating undesirable T cell responses.

BRPI0516476-1A 2004-10-05 2005-10-05 vlp antigen conjugates and their use as vaccines BRPI0516476A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61563704P 2004-10-05 2004-10-05
EP05105228 2005-06-14
PCT/EP2005/055009 WO2006037787A2 (en) 2004-10-05 2005-10-05 Vlp-antigen conjugates and their uses as vaccines

Publications (1)

Publication Number Publication Date
BRPI0516476A true BRPI0516476A (en) 2008-09-02

Family

ID=39445825

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516476-1A BRPI0516476A (en) 2004-10-05 2005-10-05 vlp antigen conjugates and their use as vaccines

Country Status (6)

Country Link
JP (1) JP2008515851A (en)
BR (1) BRPI0516476A (en)
IL (1) IL181228A0 (en)
MX (1) MX2007003954A (en)
NZ (1) NZ554388A (en)
RU (1) RU2417793C2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012125190A (en) * 2010-12-15 2012-07-05 Kakei Gakuen Linker peptide for making association unit
JPWO2022230485A1 (en) * 2021-04-26 2022-11-03
WO2024005668A1 (en) * 2022-06-28 2024-01-04 Андрей Николаевич ВОЛОГОДСКИЙ Method for producing bacteriophage virus-like particles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU764138B2 (en) * 1999-02-05 2003-08-14 Merck Sharp & Dohme Corp. Human papilloma virus vaccine formulations
CA2492826C (en) * 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use

Also Published As

Publication number Publication date
MX2007003954A (en) 2007-06-14
RU2007116717A (en) 2008-11-20
NZ554388A (en) 2010-01-29
IL181228A0 (en) 2008-04-13
JP2008515851A (en) 2008-05-15
RU2417793C2 (en) 2011-05-10

Similar Documents

Publication Publication Date Title
WO2006037787A3 (en) Vlp-antigen conjugates and their uses as vaccines
BRPI0519026A2 (en) il-15 antigen arrangements and uses thereof
Rappuoli et al. Vaccines, new opportunities for a new society
BRPI0507002A (en) vehicles ghrelin conjugates
BRPI0518761A2 (en) drug fusion, drug conjugate, Recombinant Nucleic Acid, Nucleic Acid Construction, Host Cell, Method for Producing a Drug Fusion, Pharmaceutical Composition, Drug, Method of Treatment and / or Prevention of a Condition in a Patient, Delay Method or prevention of disease progression, and a method for decreasing food absorption by a patient
AR066198A1 (en) ANTI IGE APOPTOTIC ANTIBODIES
BRPI0516775A (en) gastric inhibitor antigen (gip) polypeptide assays and their uses
BR0310088A (en) Drug pre-targeting by bispecific antibodies and haptenic constructs comprising a peptide vehicle and the active agent (s)
JP2017079745A (en) COMPLEXES OF IL-15 AND IL-15Rα AND USE THEREOF
BR112012001984B8 (en) human antibodies with high affinity for human angiopoietin-2, their use and pharmaceutical composition
BRPI0617664B8 (en) use of an antibody recognizing IL-6 for the production of a pharmaceutical composition to treat myocardial infarction or suppress left ventricular remodeling after myocardial infarction
BRPI0518101A (en) methods of production and synthesis of nanoparticulate compositions, compositions obtained and their use
BRPI0518762A2 (en) drug fusion, drug conjugate, recombinant or isolated nucleic acid, nucleic acid construct, host cell, method for producing drug fusion, pharmaceutical composition, method for treating an individual having an inflammatory disease, use of a drug conjugate or drug fusion, and, drug composition
BR112013002940A2 (en) new vaccine adjuvants based on targeting adjuvants for antibodies directly to antigen presenting cells
BRPI0415622B8 (en) use of an immortalized duck somite or retinal cell line, as well as methods for preparing an immortalized duck somite or duck retina cell line, and for virus production
NO20083062L (en) Human monoclonal antibodies to fucosyl GM1 and methods for using anti-fucosyl GM1
BRPI0612656A8 (en) immunogenic composition, vaccine, vaccine kit for concomitant or sequential administration, process for producing the vaccine, method of immunizing a human host against disease caused by neisseria meningitidis infection, and use of the immunogenic composition
BRPI0416205A (en) use of antibiotics as vaccine adjuvants
BR0209689A (en) Use of hmg fragment as anti-inflammatory agent
BR112021023048A2 (en) cd19 binding molecules and uses thereof
BR112012009289A8 (en) METHOD FOR PURIFIING AN ANTI-IL-13 ANTIBODY FROM A SAMPLE MIXTURE COMPRISING AN ANTI-IL-13 ANTIBODY AND AT LEAST ONE HOST CELL PROTEIN (HCP)
BR0207283A (en) Reduced immunogenicity modified anti-egfr antibodies
WO2013177214A3 (en) Epitope focusing by variable effective antigen surface concentration
AR083546A1 (en) TREATMENT OF GASTROINTESTINAL INFLAMMATION, SORIASIS AND ASTHMA
ECSP088636A (en) ANTIGENS OF DES-N-ACETYL-SIALIC ACID, ANTIBODIES FOR THE SAME, AND METHODS OF USE IN CANCER THERAPY

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2212 DE 28/05/2013.